The efficacy of intravenous itraconazole solubilized in hydroxypropyl-13-cyclodextrin was assessed in a rat model ofAspergillusfumigatus pneumonia. Immunosuppressed rats were infected by intratracheal inoculation ofA. fiumigatus conidia. Intravenous administration of various doses of itraconazole was started immediately after infection and continued once a day for 7 days. A 10-mg dose of intravenous itraconazole per kg was as effective on survival as 1 mg of amphotericin B per kg daily (a survival rate of 100o in 28 days), while treatment with 1 mg/kg did not increase the survival rate. The 50%o lethal dose of intravenous itraconazole given to immunosuppressed and uninfected rats for 7 days was 24.5 mg/kg/day. A microbiological assay to estimate accumulation in tissue after five daily intravenous administrations of itraconazole at 10 mg/kg showed that itraconazole and its active metabolites were present in the lungs for at least 6 h, reaching the MIC as previously described (B. Dupont and E. Drouhet, Rev. Infect. Dis. 9(Suppl. 1): 71-76, 1987; A. Espinel-Ingroff, S. Shadomy, and R. J. Gebhart, Antimicrob. Agents Chemother. 26:5-9, 1984). Intravenous itraconazole was considered to be worth evaluating in clinical trials of aspergillosis.
Itraconazole is a promising agent in treatment of aspergillosis because of its in vitro and in vivo activity against Aspergillus species (6, 7) and also because of its minimal toxicity (6, 21) . Treatment with oral itraconazole against aspergillosis has been evaluated in both animal models and clinical studies (2, 4, 6, 9, 14, 25, 26) . However, since levels of itraconazole in serum show a large degree of variation among patients (24) , because absorption varies between individuals and may be influenced by foods (29) , decisions regarding doses and evaluation of efficacy are problematic. In addition, oral treatment is sometimes difficult for the patients because of nausea, vomiting, or decreased mental ability. Therefore, intravenous administration of itraconazole should be evaluated as one approach to improving antifungal therapies. Hostetler et al. reported that hydroxypropyl-j3-cyclodextrin made itraconazole, which had poor aqueous solubility because of its hydrophobic structures, soluble and enhanced oral itraconazole absorption, as determined by bioassay (11) . We assessed the efficacy of intravenous administration of itraconazole against experimental invasive pulmonary aspergillosis by mortality in rats and studied the toxicity and levels of this agent in both serum and tissues by using immunosuppressed rats.
Efficacy of intravenously injected itraconazole. Experimental invasive aspergillosis was induced in rats as described by Schmitt et al. (22) 37°C , and the diameters of the zones of inhibition were then measured.
As shown in Table 1 , the concentrations in serum were 1.596 + 0.240 ,g/ml 10 min after injection. The levels in lungs 10 min and 6 h after injection were 0.453 ± 0.096 ,ug/g and 0.451 ± 0.101 ,g/g, respectively, higher than in livers and kidneys but lower than in spleens. At The survival kinetics of rats in the dose-response studies of intravenous itraconazole are shown in Fig. 2 . All rats in the 10-and 20-mg/kg/day administration groups survived to day 29. However, in the 30-and 40-mg/kg/day groups, all animals died by day 8. The 50% lethal dose for 7-day intravenous administration of itraconazole was 24.5 mg/kg/ day as determined by the method of Karber (12) . On the day treatment was discontinued, rats given 20 mg of itraconazole per kg per day showed weight gain (mean gain of 3.3%) while rats given 1 mg of amphotericin B per kg per day showed weight loss (mean loss of 5.8%), though the difference was not significant.
Invasive pulmonary aspergillosis is an infection caused by opportunistic fungi. Despite improvements in diagnosis (5, 8, 10, 15, 20, 28, 30) and treatment (1, 4, 13, 16, 18, 22) , invasive aspergillosis in immunocompromised patients is still a life-threatening disease. New antifungal therapies with increased efficacy and decreased toxicity are needed to improve its management. If itraconazole intravenously administered can achieve the necessary concentration, this drug may prove to be efficacious in treatment of patients.
Our therapeutic study indicated that intravenous itraconazole was effective in a model of invasive aspergillosis and prolonged survival. Graybill and Ahrens reported that oral itraconazole given to mice infected intranasally with conidia of A. fumigatus neither prolonged survival nor lowered counts ofA. fumigatus in lung tissue compared with those in control mice, in contrast to oral itraconazole in intravenously infected mice, which prolonged survival over that in controls and produced lower counts in the kidney (9) . Although we cannot compare our data to theirs because we did not use the same model, the findings of our study, employing intravenous therapy of rats infected intratracheally with conidia, are encouraging. However, histopathological studies of the lungs of surviving rats showed that seven daily intravenous injections of 20 mg of itraconazole per kg had not completely eradicated theAspergillus hyphae after 4 weeks. Niki et al. reported that rats surviving with chronic pulmonary aspergillosis showed recurrent infection when the immunosuppression was reinstituted (17) .
In our toxicity study, 20 mg/kg for 7 days was the maximum dosage to be safely administered to rats, as determined by survival rate, but nonfatal side effects were not investigated. Our study of toxicity was performed with immunosuppressed rats, and the drug was administered in a single shot. In the foundation experiments, we confirmed that the immunosuppression we used is not lethal for 30 days without infection or treatment. It is possible, however, that the immunosuppression and the rapid rate of injection of the drug contributed to the apparent toxicity. Sharkey et al. reported that toxicity is common with clinical doses of more than 400 mg of oral itraconazole per day (23) .
The MIC of itraconazole against Aspergillus spp. was reported by Espinel-Ingroff et al. to be about 0.13 ,ug/ml (7), and it was reported by Dupont and Drouhet to range from <0.09 to 0.36 ,ug/ml (6) . Concentrations of itraconazole in lungs reached the MIC and were higher than concentrations in the liver and kidneys at 10 min and 6 h after injection but lower than those in the spleen. Microbiological assay measures both the native drug and the hydroxy metabolite, preventing a direct comparison to the MIC. These properties suggest that itraconazole may be more beneficial in treatment of pulmonary infections such as aspergillosis than amphotericin B, which shows lower concentrations in lungs than in the liver and spleen in animal studies (3, 19) .
In conclusion, intravenous itraconazole effectively prolonged survival in an immunosuppressed rat model of invasive pulmonary aspergillosis. Further extensive studies could assess the potential of intravenous itraconazole as an alternative to amphotericin B for therapy of aspergillosis.
